Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Costs study in Alzheimer's disease].

J C Atance Martínez1, A Yusta Izquierdo, B E Grupeli Gardel

  • 1Hospital Provincial Ortiz de Zárate, Guadalajara.

Revista Clinica Espanola
|March 17, 2004
PubMed
Summary

Alzheimer disease (AD) poses significant socio-economic challenges, with families bearing over 60% of direct care costs. Healthcare systems must provide better support for AD patients and their families.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Biological bases of migraine].

Revista clinica espanola·2001
Same author

[Headache treatment].

Revista clinica espanola·2001
Same author

[Epidemiologic aspects of the burnout syndrome in hospital personnel].

Revista espanola de salud publica·1997
Same author

[Balint's syndrome as manifestation of Behçet's disease].

Revista clinica espanola·1992
Same author

[Spinal epidural abscess. 8 years' experience].

Revista clinica espanola·1992
Same author

[Plasma concentrations of fibronectin in septic, hypovolemic, and cardiogenic shock. Prognostic usefulness of their variation].

Medicina clinica·1992

Area of Science:

  • Gerontology
  • Public Health
  • Health Economics

Background:

  • Alzheimer disease (AD) represents a major socio-sanitary and economic burden in developed countries.
  • The aging population will increase AD incidence, intensifying the caregiving load on families.
  • Day care units offer potential for greater family independence in managing AD patient care.

Purpose of the Study:

  • To investigate the direct healthcare and social costs associated with Alzheimer disease (AD) patients in Guadalajara.
  • To evaluate global and average costs based on disease severity, sex, and age.
  • To identify key factors influencing costs, including epidemiological variables and comorbidities.

Main Methods:

  • An observational, descriptive study involving 337 AD patients from various healthcare and residential facilities in Guadalajara.
  • Data collection utilized clinical histories and hospital cost systems.
  • Statistical analysis included the Kolmorov-Smirnov test for data distribution normality (p < 0.05).

Main Results:

  • The study included 76% women, with an average age of 73.63 years; women were older on average.
  • Comorbidities were more prevalent in men. Pharmacotherapy consumption averaged 3.1 items.
  • Annual costs per patient: consultations €2,064.75, complementary explorations €639, and pharmacy €4,560. Pharmacy costs were higher for women and patients with moderate AD (II).
  • Average hospital stay was 10.8 days (€2,778 cost per admission). Primary care cost was €8,615 per patient/year.
  • Residential care costs ranged from €11,900 (private) to €12,982 (mixed administration) per patient/year.
  • Pharmacy expenses varied by AD severity: €2,470 (I), €141,359 (II), and €31,059.10 (III).

Conclusions:

  • The average cost of care is approximately three times the pensions received by AD patients.
  • Patients and/or families shoulder over 60% of the direct costs associated with Alzheimer disease.
  • Current societal and healthcare systems inadequately address the financial burden faced by families due to AD.

Related Experiment Videos